| __timestamp | Regeneron Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 5078000000 |
| Thursday, January 1, 2015 | 838526000 | 4717000000 |
| Friday, January 1, 2016 | 1177697000 | 5096000000 |
| Sunday, January 1, 2017 | 1320433000 | 4986000000 |
| Monday, January 1, 2018 | 1556200000 | 4214000000 |
| Tuesday, January 1, 2019 | 1834800000 | 3806000000 |
| Wednesday, January 1, 2020 | 1346000000 | 3671000000 |
| Friday, January 1, 2021 | 1824900000 | 3528000000 |
| Saturday, January 1, 2022 | 2115900000 | 3445000000 |
| Sunday, January 1, 2023 | 2631300000 | 3498000000 |
| Monday, January 1, 2024 | 2954400000 | 3702000000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron has seen a remarkable increase of over 400% in SG&A expenses, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Teva's SG&A expenses have decreased by approximately 31%, indicating a strategic shift towards cost optimization amidst challenging market conditions.
Regeneron's peak spending in 2023, reaching over $2.6 billion, underscores its commitment to growth, while Teva's more conservative approach, with expenses around $3.5 billion, highlights its focus on efficiency. These spending patterns not only reveal the companies' strategic priorities but also provide insights into their future trajectories in the ever-evolving pharmaceutical industry.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.